Navigation Links
Growth Opportunity in Brazil's Varicose Vein Treatment Device Market
Date:4/27/2009

Minimally invasive varicose vein treatment market is largely underpenetrated, according to Millennium Research Group

WALTHAM, Mass., April 27 /PRNewswire/ -- According to Millennium Research Group's (MRG's) Opportunities in Brazil: Varicose Vein Treatment Device Market 2009 report, Brazil is extremely underpenetrated with respect to minimally invasive varicose vein treatment devices. The varicose vein treatment device market in the country, widely considered to be one of the most aesthetically-conscious in the world, is limited primarily by the Brazilian universal public health system, which provides reimbursement for surgical vein removal (stripping) procedures but not for more advanced, minimally invasive procedures such as endovenous ablation and sclerotherapy. As a result, patients must pay for these treatments out-of-pocket. Nevertheless, procedure volumes for these minimally invasive alternatives will increase by approximately 10% annually from 2009 to 2013 due to growing patient demand for the superior cosmetic results and reduced postoperative pain associated with these therapies.

Surgical stripping currently remains the gold standard for varicose vein treatment in Brazil because the procedure is extremely cost-effective for the patient and physicians do not need to purchase capital equipment in order to perform the procedures. Surgical stripping is, however, a highly traumatic procedure for the patient, and recovery time is much longer than with newer, minimally invasive treatments. Because the government does not cover the costs for the minimally invasive alternatives, which can cost the patient approximately $1500 per procedure, patients must pay completely out-of-pocket. In contrast, the cost to the patient for a surgical stripping and ligation procedure in the public system, coupled with a 2-night stay in the hospital, is approximately $300, making surgical stripping one of the most affordable treatment options for varicose veins in all of Latin America.

"It is virtually impossible for newer, more expensive treatments to compete within the public health system," says Darren Navarro, Senior Analyst at MRG. "Instead, use of these newer technologies remains confined to the private health system, which serves a more affluent demographic in Brazil. Foreign device manufacturers planning to enter the Brazilian market will need to fully understand Brazil's driving and limiting factors in order to optimize market entry and capitalize on this underpenetrated market."

MRG's Opportunities in Brazil: Varicose Vein Treatment Device Market 2009 report provides coverage of key competitors, including AngioDynamics, biolitec, Codman, Dornier Medtech, Helmeyster, LeMaitre Vascular, MedArt, Vascular Solutions, VNUS Medical Technologies, and more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Biometric Market - A Recession Proof Area of Growth and Opportunities, Says Frost & Sullivan
2. Statins may exert influence on prostate cancer growth by reducing inflammation
3. Growth of Plastic Surgery & Botox Grannies in UK
4. STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase
5. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
6. Researchers find drug that inhibits acute leukemia cell growth
7. Novel cancer drug reduces neuroblastoma growth by 75 percent
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
9. Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009
10. Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth
11. Saebo United Kingdom Posts Record 2008; Sees Continued Growth in UK for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing dual ... opening of the Sober College Robert Pfeifer Memorial Learning Center at its location ... was attended by an overwhelming amount of alumni, family, colleagues and friends of ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Allergy Diagnostics Market: Scope and ... that are used to determine the presence of ... drugs etc. in the samples by determining the ... The report on global allergy diagnostics market, analyzes ... The report consists of an executive summary that ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Dec. 8, 2016  Valeant Pharmaceuticals International, Inc. ... ("Valeant") today announced positive results from a Phase ... assess the safety and efficacy of IDP-118 (halobetasol ... plaque psoriasis. Within the Phase ... to severe psoriasis, IDP-118 showed statistical significance to ...
Breaking Medicine Technology: